Roivant Sciences
ROIV
260 hedge funds and large institutions have $5.6B invested in Roivant Sciences in 2024 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 91 increasing their positions, 64 reducing their positions, and 34 closing their positions.
106% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 34
42% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 64
16% more funds holding
Funds holding: 225 → 260 (+35)
1.41% less ownership
Funds ownership: 67.38% → 65.97% (-1.4%)
8% less capital invested
Capital invested by funds: $6.08B → $5.6B (-$478M)
10% less funds holding in top 10
Funds holding in top 10: 21 → 19 (-2)
18% less call options, than puts
Call options by funds: $11.2M | Put options by funds: $13.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$166M |
| 2 |
Morgan Stanley
New York
|
+$148M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$54.1M |
| 4 |
PC
PointState Capital
New York
|
+$43.6M |
| 5 |
State Street
Boston,
Massachusetts
|
+$36.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
QF
QVT Financial
New York
|
-$494M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$146M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$69.4M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$34.4M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$28M |
ROIV Hedge Fund Activity: Q1 2024 in Review
260 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Roivant Sciences (ROIV) for Q1 2024, worth a combined $5.6B — down 7.9% from $6.08B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new ROIV positions and 34 closed out — a net gain of 36 holders — while 91 added to existing stakes and 64 trimmed.
The largest buyer was BlackRock, adding an estimated $166M. The largest seller was QVT Financial, cutting an estimated $494M.
- 260 institutional investors held Roivant Sciences (ROIV) as of Q1 2024, up from 225 in Q4 2023.
- Funds reported $5.6B of Roivant Sciences stock for Q1 2024, down 7.9% quarter-over-quarter.
- 70 funds opened new Roivant Sciences positions in Q1 2024 and 34 closed out, a net change of +36 holders.
- The largest Roivant Sciences buyer in Q1 2024 was BlackRock, an estimated $166M added.
- The largest Roivant Sciences seller in Q1 2024 was QVT Financial, an estimated $494M sold.
Based on aggregated 13F filings for Q1 2024.